Shares of Fisker Inc. (FSR) rallied 1.2% in premarket trading Tuesday, as the electric vehicle maker announced significant advancements in enhancing its service capabilities. Chief Executive Henrik Fisker stated, "We realize, based on customer feedback, that we need to make improvements, so we are ramping up our service operations globally, enhancing our service process and growing our service team."
Strengthening Technical Expertise and Expanding Repair Network
Fisker Inc. has responded to customer demands by significantly increasing recruitment efforts for technicians. Currently, the company employs nearly 100 technicians and has established 35 repair shops within its network.
Over-the-Air Updates for Improved Performance
The company has been diligently rolling out over-the-air software updates for its Fisker Ocean vehicle. This update process aims to enhance vehicle performance and functionality. It is expected that all Fisker vehicles will have completed the update by the end of January.
Positive Stock Movement
Despite a 74.3% decline over the past three months, Fisker's stock has shown a 14.9% increase since reaching a record low of $1.41 on December 6th. In comparison, the Global X Autonomous & Electric Vehicles ETF (DRIV) has experienced a modest 0.1% increase during the same period, while the S&P 500 (SPX) has gained 6.7%.
Fisker Inc. is committed to providing exceptional service and continued improvement for its customers globally.
Related Articles
CarMax Reports Decline in Fiscal Second-Quarter Revenue
CarMax experiences a decline in revenue for Q2, with used-vehicle unit sales falling and earnings per share lower than the previous year. Factors such as inflat...
Technology Stocks Soaring Despite High Prices
Technology stocks are defying conventional trends, rallying despite rising bond yields and high valuations, driven by market expectations and aggressive earning...
Galera Therapeutics Faces Setback in FDA Approval Process
Galera Therapeutics faces setback as FDA demands Phase 3 trial for oral mucositis treatment. Stock plummets and trials paused as company explores strategic alte...